Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (NKTR) is a clinical-stage biopharmaceutical company pioneering novel immunotherapies for autoimmune disorders and chronic inflammatory diseases. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements and corporate developments.
Access authoritative information on NKTR's pipeline progress, including updates on rezpegaldesleukin (Treg stimulator) and NKTR-255 (IL-15 agonist). Our curated collection features press releases about clinical trial milestones, regulatory submissions, strategic partnerships, and financial disclosures.
Key content categories include therapy development breakthroughs, FDA communications, research collaborations, and manufacturing updates. All materials are sourced directly from official company channels to ensure accuracy and compliance.
Bookmark this page for streamlined access to NKTR's latest developments in polymer conjugate chemistry and immunomodulation research. Check regularly for updates that could inform your understanding of the company's scientific trajectory and market position.
Nektar Therapeutics (NKTR) has announced its management's participation in two upcoming investor conferences. The first is the H.C. Wainwright 26th Annual Global Investment Conference in New York City on September 9, 2024 at 3:00 p.m. ET. The second is the Stifel Virtual Immunology and Inflammation Summit on September 17, 2024 at 12:30 p.m. ET.
Both presentations will be accessible via webcast through the Investor Events section of Nektar's website. The webcasts will remain available for replay until October 9, 2024 and October 17, 2024, respectively, allowing investors and interested parties to access the information even after the live events.
Nektar Therapeutics (NKTR) reported Q2 2024 financial results with revenue of $23.5 million, up from $20.5 million in Q2 2023. The company's cash position was $290.6 million as of June 30, 2024, expected to support operations into Q3 2026. Net loss for Q2 2024 was $52.4 million or $0.25 per share. Nektar is progressing with Phase 2 studies of rezpegaldesleukin in atopic dermatitis and alopecia areata, with topline data expected in H1 and mid-2025, respectively. The company is also advancing NKTR-0165, a TNFR2 agonist antibody, towards IND submission in mid-2025. Recent data on NKTR-255 in combination with CAR-T therapy showed promising results in B-cell acute lymphoblastic leukemia patients.
Nektar Therapeutics (Nasdaq: NKTR) has announced that it will release its financial results for the second quarter of 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. The company's President and CEO, Howard Robin, will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time to review the results.
Investors and interested parties can access the press release and live audio-only webcast of the conference call through a link on the Home Page and Investors section of Nektar's website. The web broadcast will be available for replay until September 8, 2024. To participate in the conference call, pre-registration is required through the Nektar Earnings Call Registration link.
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associated with various autoimmune diseases like ulcerative colitis and vitiligo. Preclinical studies revealed that NKTR-0165 enhances Treg cell function, a key component in immune response regulation, without affecting TNFR1 signaling. IND-enabling studies are ongoing, with human trials expected in the first half of 2025.
Nektar Therapeutics (Nasdaq: NKTR) management will present at two upcoming investor conferences: the Jefferies Healthcare Conference in New York City on June 6, 2024, at 3:30 p.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024, at 2:00 p.m. ET.
The presentations will be webcast live and accessible via the Investor Events section on the Nektar website. Recordings of the webcasts will be available until July 6, 2024, and July 10, 2024, respectively.
Nektar Therapeutics reported their financial results for the first quarter of 2024, showing revenue of $21.6 million and a net loss of $36.8 million. The company's cash and investments were $326.0 million as of March 31, 2024, supporting operations until the third quarter of 2026. Progress was noted in their immunology and inflammation pipeline, with expectations for topline data from ongoing trials in 2025. Nektar also entered into a private placement financing agreement generating $30 million in gross proceeds.
Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and CEO, will host a conference call to review the results. The press release and webcast link will be available on the Nektar website. Conference call replay will be accessible until June 9, 2024.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
